In addition, HMGB1/TLR4, a therapeutic target for severe pneumonia, including COVID‐19, mediates the release of proinflammatory cytokines, and acetylcholine, heparin, statins, glycopyrrolate, ketamine, and resveratrol are important drug candidates as TLR4 inhibitors.243. This evidence concerns the gene TLR4 and susceptibility to pneumonia measurement.